Department of Neuroscience, University of Turin Medical School, Turin, Italy.
Plateau Rosa Laboratories, Breuil-Cervinia, Italy, Zermatt, Switzerland.
Mov Disord. 2017 Oct;32(10):1474-1478. doi: 10.1002/mds.27142. Epub 2017 Sep 12.
Placebo effects represent a major drawback in clinical trials, and their magnitude hampers the development of new treatments. Previous research showed that prior exposure to active treatments increases the placebo response for muscle rigidity in Parkinson's disease.
We investigated the effects of prior exposure to apomorphine on the placebo response of another cardinal symptom of Parkinson's disease, bradykinesia, by a movement time analyzer.
We found no placebo response if the placebo was given for the first time, whereas the placebo response was substantial after prior pharmacological conditioning with apomorphine.
These findings indicate that prior exposure to drugs is a critical factor in the occurrence and magnitude of placebo effects. These learning effects should be carefully assessed in clinical trials in which patients receive the active treatment first and then are randomized. Indeed, this sequence may generate high placebo responders. © 2017 International Parkinson and Movement Disorder Society.
安慰剂效应是临床试验中的一个主要缺陷,其程度阻碍了新治疗方法的发展。先前的研究表明,先前接触过有效治疗会增加帕金森病肌肉僵直的安慰剂反应。
我们通过运动时间分析仪研究了先前接触阿扑吗啡对帕金森病另一个主要症状——运动迟缓的安慰剂反应的影响。
如果首次给予安慰剂,则没有安慰剂反应,而在先前用阿扑吗啡进行药物调理后,安慰剂反应明显。
这些发现表明,先前接触药物是安慰剂效应发生和程度的关键因素。在患者首先接受有效治疗然后随机分组的临床试验中,应仔细评估这些学习效应。事实上,这种顺序可能会产生高安慰剂反应者。© 2017 国际帕金森病与运动障碍学会。